8-K: Harrow Reports Q1 2026 Results Amidst VEVYE Coverage Adjustments

Harrow, Inc. announced its first quarter 2026 financial results, highlighting strong demand for key products like VEVYE, IHEEZO, and TRIESENCE, while addressing a non-recurring revenue adjustment impacting reported figures.

Summary

• Harrow, Inc. reported first quarter 2026 financial results, with total revenues of $44.2 million, an 8% decrease year-over-year.
• The company experienced a non-recurring gross-to-net revenue adjustment related to new VEVYE commercial coverage, which reduced Q1 revenue by approximately $8 million.
• Despite this adjustment, demand for key products remained strong: VEVYE saw prescription growth, IHEEZO unit demand increased 18% year-over-year, and TRIESENCE unit demand more than doubled.
• The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and expects VEVYE revenue to exceed $100 million for the year.
• Cash and cash equivalents stood at $94.6 million as of March 31, 2026.
• The company is expanding its commercial organization, with over 100 representatives hired.
• Second quarter revenue is expected to be between $71 million and $81 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While underlying demand for key products is strong and future guidance is reaffirmed, the significant increase in net loss and worsening Adjusted EBITDA, coupled with a revenue decline and a substantial gross-to-net adjustment, present considerable headwinds.

Positives

• VEVYE delivered record new and total prescription performance, surpassing XIIDRA on a monthly total prescription basis and achieving approximately 14% market share.
• IHEEZO unit demand increased 18% year-over-year, with strong adoption in retina accounts.
• TRIESENCE unit demand more than doubled year-over-year, marking the sixth consecutive quarter of growth.
• Full-year 2026 revenue guidance of $350 million to $365 million was reaffirmed.
• VEVYE demand growth is on track to deliver over $100 million in revenue for 2026.
• The company successfully expanded its commercial organization by hiring over 100 representatives.
• Cash and cash equivalents increased to $94.6 million as of March 31, 2026.

Negatives

• Total revenues for the first quarter of 2026 were $44.2 million, a decrease from $47.8 million in the prior-year period.
• A non-recurring gross-to-net revenue adjustment for VEVYE reduced Q1 revenue by approximately $8 million.
• GAAP net loss for the first quarter of 2026 was $27.6 million, an increase from $17.8 million in the prior-year period.
• Adjusted EBITDA for the first quarter of 2026 was $(12.7) million, a significant decrease from $(2.0) million in the prior-year period.
• GAAP gross margins decreased to 61% from 68% year-over-year, primarily due to lower net revenue per unit of VEVYE and lower compounding facility utilization.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement business plan, develop and commercialize products.
• Product candidate development and commercialization timelines.
• Identifying and acquiring additional products.
• Managing pharmacy operations and servicing debt.
• Obtaining necessary financing.
• Recruiting and retaining qualified personnel.
• Managing growth and realizing benefits from acquisitions.

Future Outlook

The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and expects VEVYE revenue to exceed $100 million for the year. Second quarter revenue is projected to be between $71 million and $81 million. Management expresses high confidence in achieving these objectives due to strong underlying demand, an expanding sales funnel, and the deployment of a scaled commercial organization.

Management Comments

• "The demand for Harrows key products has never been stronger, and our visibility into our demand trajectory across our portfolio keeps us entirely on track to reach our forecasted financial goals for the year."
• "Although our first-quarter reported revenue reflects an estimated $8 million gross-to-net reduction associated with our new commercial coverage for VEVYE, this adjustment does not reflect the profitable, recurring, and significant patient base established during the quarter."
• "Harrow is now positioned to realize the full financial benefits of this coverage relationship beginning in Q2 2026."
• "Our core commercial engine is accelerating. VEVYE delivered record prescription performance and has officially surpassed XIIDRA on a monthly total prescription basis."
• "With our expanded commercial organization now fully deployed, we remain highly confident in our ability to deliver on our 2026 revenue guidance of $350 million to $365 million."
• "my confidence in Harrows future has never been higher, and the company we own has never been more valuable."
• "Based on demand trends we are seeing and the visibility we have into our forward sales funnel, I am confident in our ability to deliver on our 2026 guidance."

Industry Context

StockSavvy.ai notes that Harrow's Q1 2026 results reflect a common challenge in the pharmaceutical sector: managing gross-to-net deductions, particularly with new commercial coverage. The company's performance in a declining dry eye market, with VEVYE gaining share, highlights its ability to execute despite broader category headwinds. The expansion of its sales force and focus on key growth drivers like IHEEZO and TRIESENCE align with industry trends of specialized product development and market penetration.

Comparison to Industry Standards

• The overall branded dry eye category experienced an approximate 18% decline in Q1 2026, while VEVYE demonstrated significant prescription growth, indicating market share gains against industry contraction.
• IHEEZO's 18% year-over-year unit demand increase and 82% from retina accounts suggests strong adoption within a specialized segment of the ophthalmic market.
• TRIESENCE's unit demand doubling year-over-year indicates successful penetration and growth in its surgical inflammation market, outperforming general market trends.
• The company's reaffirmation of full-year revenue guidance aligns with typical investor expectations for companies demonstrating consistent demand drivers, even with short-term revenue adjustments.

Stakeholder Impact

• Shareholders: The increased net loss and worsened Adjusted EBITDA may negatively impact investor sentiment in the short term, despite reaffirmed full-year guidance and strong underlying demand.
• Employees: The hiring of over 100 representatives indicates investment in the sales force, potentially leading to increased opportunities and workload.
• Customers (Physicians/Patients): The VEVYE gross-to-net adjustment may have temporarily impacted patient out-of-pocket costs, though the company aims for long-term patient benefit. Continued strong demand for IHEEZO and TRIESENCE suggests positive clinical utility and practice integration.
• Suppliers: Not explicitly mentioned, but increased operational activity may lead to higher demand for raw materials or services.

Next Steps

• Realize full financial benefits of VEVYE coverage relationship beginning in Q2 2026.
• Continue to drive VEVYE prescription growth and market share gains.
• Leverage expanded sales force to accelerate commercial execution.
• Launch BYOOVIZ biosimilar in Q3 2026.
• Advance clinical studies for IHEEZO (ASRS in July, QUELL study in Q4).
• File NDA for G-MELT within the next 12 months.
• Present filing to FDA for TRIESENCE PFS format within 18-20 months.
• Develop strategic plan for 2027-2031.

Key Dates

Recommendation

The company reaffirms its full-year guidance despite a challenging Q1 with increased losses and a significant revenue adjustment. Strong product demand and strategic initiatives like the BYOOVIZ launch offer potential upside, but the worsening financial metrics and the impact of the VEVYE adjustment warrant a cautious 'hold' stance until Q2 results demonstrate recovery and the impact of the expanded sales force becomes clearer.

Keywords

Harrow Inc, HROW, Ophthalmic disease management, VEVYE, IHEEZO, TRIESENCE, Financial Results, SEC Filing